Retinal imaging platform wins FDA breakthrough designation
American Academy of Ophthalmology News May 16, 2019
Optina Diagnostics has received the breakthrough device designation from the US Food and Drug Administration (FDA) for their retinal scanner designed to aid in the early detection of Alzheimer disease.
The platform utilizes artificial intelligence to identify beta-amyloid (AB) plaques—a key biomarker of Alzheimer disease—from simple eye scans. Optina hopes their approach will offer an inexpensive and convenient alternative to amyloid PET scans, and a higher diagnostic accuracy than using clinical symptoms.
"Optina Diagnostics' technology based on data-rich hyperspectral retinal imaging combined with AI opens tremendous possibilities to have insights into the brain non-invasively and at a low cost,” explained the company’s CEO, David Lapointe. “The Optina Diagnostics technology could also be helpful to accelerate and reduce the cost for the enrollment of participants that are really on the Alzheimer's path to conduct clinical trials for disease-modifying drugs for Alzheimer disease.”
The Montreal-based company sees their platform as an adjunct to other diagnostic methods for evaluating Alzheimer disease and other causes of cognitive decline.
Sign-up to continue reading. It is free & takes less than 2 mins
-
45 lakhs+ doctors trust M3 globally
-
Free & unlimited access to original articles and quizzes
-
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitions
Try M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor